In this episode, ‘Hypercortisolism and Cardiovascular Risk Management,’ the panelists explore the broader implications of hypercortisolism on cardiovascular risk and the role of cardiologists in comprehensive patient management. The panelists emphasize that hypercortisolism should not be viewed solely as an endocrine disorder, but rather as a condition deeply intertwined with cardiovascular disease, including atrial fibrillation, heart failure, coronary artery disease, and chronic kidney disease.

The expert panel highlights that patients with hypercortisolism represent a particularly high-risk population, requiring aggressive and holistic risk factor management. In addition to addressing the underlying cortisol excess, faculty stress the importance of optimizing lipid control, screening for additional risk markers, and managing comorbidities across the cardiovascular spectrum. The discussion reinforces the need to move beyond isolated treatment of hypertension or diabetes and instead adopt a global risk reduction strategy.

Importantly, the panelists introduced the concept of interconnected cardiometabolic systems, aligning with emerging frameworks such as cardiovascular-kidney-metabolic care. They also highlight the need for future research to better define the impact of treating hypercortisolism on cardiovascular outcomes. Overall, the expert faculty underscore a shift toward integrated, multidisciplinary care and the identification of hypercortisolism as a key driver of residual cardiovascular risk.

The next episode in this series, ‘Emerging Therapies in Hypercortisolism,’ features the panelists discuss emerging therapies and future directions in hypercortisolism treatment. The panel highlights the need for simpler, effective therapies to drive broader diagnosis and care.